Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In male pattern hair loss, this study found that finasteride 1 mg daily significantly slowed hair loss and increased hair growth over two years compared to placebo.

This review discusses the role of 5α-reductase in prostate development and BPH, and reports no new clinical results; ongoing trials are exploring dual isozyme inhibitors for improved treatment efficacy.

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

This article reviews the historical developments in understanding and treating male pattern hair loss, emphasizing the role of dihydrotestosterone and 5α-reductase inhibitors, but reports no new clinical findings.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This article discusses treatment options for androgenetic alopecia, noting that medical interventions like finasteride and minoxidil can halt and partially reverse hair loss in mild to moderate cases, especially when combined with surgery.

This study found that oral finasteride was more effective than 5% topical minoxidil in treating mild to severe androgenetic alopecia in males, with both treatments deemed effective and safe over 12 months.

This review discusses various substances that can impact male fertility and stresses that products should be confirmed 'sperm-safe' through rigorous testing, not assumptions; it reports no new study results.

This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.

This study found that discontinuing finasteride led to a significant increase in sperm counts for most men with reduced fertility, though hormone levels and other semen parameters remained unchanged.

This review discusses the pathogenesis and treatment of androgenetic alopecia, highlighting genome associations and newer topical formulations, but reports no new clinical results.

In this study, 68% of patients treated with finasteride showed improved hair growth in male androgenetic alopecia, compared to 38% with Serenoa repens, indicating finasteride's superior efficacy.

This review assesses the current literature on COVID-19's effects on male sexual and reproductive health, highlighting significant research gaps and providing guidance for patient counseling.

This study found that men experiencing long-term symptoms after finasteride use for androgenetic alopecia frequently reported loss of penis sensitivity and anhedonia, among other effects, indicating potential post-finasteride syndrome.

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

This article reviews current guidelines for managing androgenetic alopecia and highlights the need for guidelines tailored to Japan; it reports no new clinical results.

This study concluded that five-alpha-reductase inhibitors may reduce prostate cancer risk but could increase the risk of high-grade prostate cancer in men regularly screened for the disease.

This study found that finasteride (1 mg) significantly increased hair growth in all scalp regions affected by male pattern hair loss over 24 months in men aged 18 to 60, with more pronounced effects in younger men.

This review examines medical literature on postfinasteride syndrome and reports no new results; the authors call for more controlled studies on permanent sexual dysfunction and mood changes linked to 5-alpha-reductase inhibitors.

In this study, finasteride was found to be more effective than 5% minoxidil for treating male androgenetic alopecia in Chinese patients, with combination therapy showing the greatest improvement.

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.

This review discusses the efficacy and safety of 5-alpha reductase inhibitors for treating androgenetic alopecia, noting concerns about sexual side effects, which are typically uncommon and often resolve over time.

This review discusses the hormonal influences on prostate carcinogenesis and notes ongoing trials investigating whether finasteride could reduce prostate cancer incidence by inhibiting dihydrotestosterone synthesis, but it reports no new results.

This study found that reproductive gynecologists are the primary source of referrals for male infertility evaluations, with many men referred before completing a male factor investigation even when using assisted reproductive technologies or lifestyle factors like testosterone replacement.

In this randomized clinical trial, the authors reported that adipose-derived stem cell constituent extract topical solution increased hair density and thickness in patients with androgenetic alopecia over 16 weeks compared to placebo.

This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.

This article discusses androgenetic alopecia and reports no new clinical results.

This review discusses cross-sex hormone therapy for managing gender dysphoria in transsexual individuals and reports no new clinical results; it highlights the need for education and culturally sensitive training for healthcare professionals.

In this laboratory study with rats, treatment with finasteride reduced dihydrotestosterone levels and fertility parameters, with a 30-day recovery period proving insufficient to fully restore sperm function and fertility.

This review discusses the role of androgen hormones in skin and hair conditions and highlights the potential of antiandrogen therapies in dermatology, reporting no new results.